Compare Live Nation Entertainment, Inc. (LYV) vs Moderna, Inc. (MRNA) Price & Performance

Live Nation Entertainment (LYV) trades at $170.84, down 0.55% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 earnings beat with 1.05 EPS versus 0.66 expected, though Q1 and Q4 2025 missed estimates. Revenue growth continues with $25.2B in 2025, while net income margin remains thin at 0.51%. Analyst consensus is strongly bullish with 87% buy ratings and a $208.18 price target, representing 22% upside potential.

LYV benefits from strong consumer demand for live events ('funflation' trend) and record deferred revenue of $6.4B, but faces execution risks from cost pressures, legal uncertainties, and high debt levels. The stock's elevated P/E of 117.5 reflects growth expectations, making it sensitive to earnings delivery. Near-term support sits at $169 with resistance at $172.

Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.

While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.